Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.63 |
|---|---|
| High | 0.63 |
| Low | 0.63 |
| Bid | 0.575 |
| Offer | 0.590 |
| Previous close | 0.665 |
| Average volume | 2.11k |
|---|---|
| Shares outstanding | 106.67m |
| Free float | 99.74m |
| P/E (TTM) | -- |
| Market cap | 77.89m USD |
| EPS (TTM) | -0.4298 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 07:00 GMT.
More ▼
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
- MaxCyte Announces Planned CFO Transition in 2026
- MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
- MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
- MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
- MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
- MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
- MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
- MaxCyte Signs Platform License Agreement with Adicet Bio
- MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
More ▼
